<DOC>
	<DOC>NCT00601887</DOC>
	<brief_summary>The objective of this study was the bioequivalence of a Roxane Laboratories' Meloxicam tablets, 15 mg, to MobicÂ® Tablets, 15 mg (Boehringer Ingelheim) under fed conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.</brief_summary>
	<brief_title>Bioequivalency Study of Meloxicam Tablets Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Meloxicam or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Anti-inflammatory</keyword>
</DOC>